Plain-English translation of NCT07351734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called JKN2403 can help people with moderate to severe COPD (a lung disease that makes it hard to breathe). Researchers will give some participants the medication at different doses while others receive a placebo (a pill with no active drug), and they'll track how well the treatment works compared to placebo over 24 weeks.
Current treatments don't work well enough for everyone with COPD, and doctors need new options to help reduce flare-ups and improve breathing. This trial will help determine if this medication could be a helpful addition to standard treatment.
You likely qualify if…
You likely don't qualify if…
You will take a daily tablet (either the medication or placebo) for 24 weeks. You'll visit the clinic about every four weeks for checkups and tests to see how your lungs are doing. Between visits, you'll keep a simple diary tracking your breathing symptoms and how often you use your rescue inhaler. This helps researchers understand whether the treatment is working for you.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China